As the list of COVID-19-associated pathophysiology linked to deregulated complement activation grows longer, it has become clear that complement inhibitors against C3 or C5 or activating pathways open new windows of therapeutic opportunity for treatment with severe COVID-19 cases. This evidence concerns the gene C3 and COVID-19.